Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer

Inclusion Criteria:

* Patients with inoperable pancreatic cancer (ICD-10 C25.0-3) at the Department of Surgical Gastroenterology of Haukeland University Hospital, who have volunteered to participate

Exclusion Criteria:

* Patient participated in an investigational study within 30 days prior to study entry (or, if longer, within five half-lives of the last dose of any investigational drug).
* Patient has severe chronic obstructive pulmonary disease or severe chronic asthma.
* Patient has a history of cardiovascular ischemia, acute myocardial infarction or unstable angina within 3 months prior to study entry.
* Patient has a history of any psychiatric disorder or cognitive impairment that would interfere with participation in the study.
* Patient has a known history of Hepatitis B, Hepatitis C or HIV infection.
* Patient requires dialysis or has severely impaired renal function, defined as a serum creatinine \> 180 mmol/L at the Screening Visit.
* Patient has severe impairment of liver function, defined as a serum albumin level ≤ 25 g/L and/or a Protrombin Time INR \> 2.3 (or APTT \> 6 seconds above the upper limit of normal) at the Screening Visit.
* Patient is pregnant or is breast-feeding.
* Patient is allergic to or intolerant of gemcitabine
* Patient is allergic to or intolerant of SonoVue® BRACCO ultrasound contrast agent
* Any reason why, in the opinion of the investigator, the patient should not participate.